Background: Rituximab, a monoclonal anti-CD20 antibody, is increasingly used to treat
idiopathic thrombocytopenic purpura (ITP). Purpose: To systematically review the literature …

The use of rituximab for the treatment of immune thrombocytopenia was greeted
enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main …

Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated
platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk …

Treatments for immune thrombocytopenic purpura (ITP) providing durable platelet
responses without continued dosing are limited. Whereas complete responses (CRs) to B …

Whether rituximab could effectively and safely avoid splenectomy for adults with chronic
immune thrombocytopenic purpura (ITP) remains unresolved. A multicenter, prospective …

Current treatment regimens for haematological autoimmune diseases are relatively non‐
selective and are often associated with considerable toxicity. Recently, it has become clear …

This study aimed to compare the efficacy and safety of rituximab (RTX) plus recombinant
human thrombopoietin (rhTPO) with RTX alone in patients with immune thrombocytopenia …

Abstract Backgrounds: Rituximab 375 mg/m2 weekly for 4 wks has significant activity in
adults with primary immune thrombocytopenia (ITP). In this setting, several evidences …

Introduction Primary immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by a low platelet count (< 100× 109/L) with an increased risk of bleeding …

Primary immune thrombocytopenia (ITP) is an acquired immune‐mediated disorder with
absence of any underlying cause. Corticosteroids are the standard initial treatment …